Literature DB >> 7693035

V gene usage by seven hybrids derived from CD5+ B-cell chronic lymphocytic leukemia and displaying autoantibody activity.

O Pritsch1, C Magnac, G Dumas, C Egile, G Dighiero.   

Abstract

We report here the complete heavy and light chain variable region sequences of seven heterohybridomas derived from CD5+ chronic lymphocytic leukemia (CLL) B lymphocytes and displaying natural autoantibody activity. The three hybrids displaying a polyreactive pattern of binding used VH4 family members, ie, the VH4-18 gene in germinal configuration in two cases and a VH4 gene with 90% homology with VH4-21 for the third one. A hybrid expressing anti-Sm activity used a VH3 family member with 95.26% homology with the 30P1 gene. The three hybrids exclusively displaying rheumatoid factor activity expressed VH1 family genes: 51P1 gene for two (in germinal configuration in one, and with 93.2% homology in the other), whereas the third one used the V1-3b gene (98.8% homology). Definitive homology with known germline D segments was found for four of the seven hybrids (DN2 in 3 and DLR4 in 1) and JH use appeared to be random. The three hybrids displaying polyreactive activity expressed V kappa I, V lambda III, and V lambda II genes, all in germinal configuration. Among the three hybrids with rheumatoid factor activity, two used the same V kappa II gene with, respectively, 98% and 96% homology with a gene previously described; the third used a V lambda I gene in germinal configuration. Finally, the clone with anti-Sm activity used a V lambda III gene having 97% homology with a germinal gene. Overall, these results attempt to establish the relationship between frequent self-reactivity observed in CD5+ B-CLL and V gene usage. For VH genes, they confirm overexpression of the 51P1 gene in B-CLL and suggest nonstochastic use of two VH4 genes (4-21 and 4-18). For VL genes, available information is too scarce to lead to firm conclusions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity.

Authors:  Ibrahim Koral Onal; Levent Ozçakar; Omer Dizdar; Yahya Büyükaşik; Semra Dündar
Journal:  Rheumatol Int       Date:  2005-03-11       Impact factor: 2.631

2.  Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.

Authors:  Roberto Negro; Stefania Gobessi; Pablo G Longo; Yantao He; Zhong-Yin Zhang; Luca Laurenti; Dimitar G Efremov
Journal:  Blood       Date:  2012-05-08       Impact factor: 22.113

3.  SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers.

Authors:  Alejandro Roisman; Carmen Stanganelli; Virginia Palau Nagore; Guillermo Videla Richardson; María Elida Scassa; Raimundo Fernando Bezares; María Cabrejo; Irma Slavutsky
Journal:  Tumour Biol       Date:  2015-01-22

4.  Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells.

Authors:  B W Long; P L Witte; G N Abraham; S A Gregory; J M Plate
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

6.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

7.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.

Authors:  Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

8.  VDJSeq-Solver: in silico V(D)J recombination detection tool.

Authors:  Giulia Paciello; Andrea Acquaviva; Chiara Pighi; Alberto Ferrarini; Enrico Macii; Alberto Zamo'; Elisa Ficarra
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

9.  A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors.

Authors:  Jerry Janssen; Naomi Donner; Zhen Li; Thera A M Wormhoudt; Koen Wagner; Jeroen E J Guikema; C Ellen van der Schoot; Arnon P Kater; Ten Feizi; Richard J Bende; Carel J M van Noesel
Journal:  Hemasphere       Date:  2021-03-23

10.  Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.

Authors:  S Hashimoto; M Dono; M Wakai; S L Allen; S M Lichtman; P Schulman; V P Vinciguerra; M Ferrarini; J Silver; N Chiorazzi
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.